Oncolytics Says Preclinical Results Back Further Evaluation of Pelareorep Plus RAS-Targeted Approaches

MT Newswires Live06-01

Oncolytics Biotech (ONCY) said Monday that initial results from a preclinical study assessing pelareorep plus RAS inhibitor modalities in a solid tumor model showed evidence of the combination's greater anti-tumor activity than with the individual approaches alone.

The company said that, based on the results, it is planning further studies in models of pancreatic ductal adenocarcinoma and colorectal cancer to further assess the combinations' anti-tumor and immune effects.

Full results from the initial preclinical studies are slated to be presented in the fall or winter of this year, Oncolytics said.

The company's shares were up more than 8% in Monday premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment